latest news releases from the newsroom
BILIA TO START SELLING KIA
Motoria Bil AB, one of Bilia's subsidiaries, is going to start selling the
South-Korean car brand, Kia.
"Selling Kia is an exciting challenge for our group," says Jan Pettersson,
managing director of Bilia AB. Kia, which is part of the Hyundai-Kia Automotive
Group, is aiming to be one of the world's leading car brands and is the brand
in Europe that experienced the largest growth in 2004.
"Kia operations will be run in a separate company, Motoria Bil AB, at a new
sales facility in Kista in
CORRECTION: AB Volvo repurchased 500,000 series B shares and 15,000 series A shares
GOTEBORG, Sweden, Feb. 14, 2005 (PRIMEZONE) -- Further to the decision taken by AB Volvo's Board of Directors on June 17, 2004, regarding repurchase of own shares, AB Volvo has, on Friday, February 11, acquired 500,000 series B shares. The shares were traded between SEK 298.50 and 301.50 with an average price of SEK 300.30 and 15,000 series A shares. The shares were traded between SEK 288.50 and 291.50 with an average price of SEK 290.23.
AB Volvo announces repurchase of 500,000 B shares and 17,000 A shares
GOTEBORG, Sweden, Feb. 14, 2005 (PRIMEZONE) -- Further to the decision taken by AB Volvo's Board of Directors on June 17, 2004, regarding repurchase of own shares, AB Volvo has, on Friday, February 11, acquired 500,000 series B shares. The shares were traded between SEK 298.50 and 301.50 with an average price of SEK 300.30 and 17,000 series A shares. The shares were traded between SEK 288.50 and 291.50 with an average price of SEK 290.23.
Xenova Group PLC
Xenova Group plc -- TransMID Obtains Orphan Drug Designation in Japan
SLOUGH, U.K., Feb. 14, 2005 (PRIMEZONE) -- Xenova Group plc (Nasdaq:XNVA) (LSE:XEN) today announced that, Sosei Co. Ltd. (Sosei) (4565, Tokyo Stock Exchange MOTHERS Index), its licensee for the Japanese market, has been granted orphan drug status for the use of TransMID(TM) in the treatment of glioma (a type of brain cancer) by the Ministry of Health, Labour and Welfare (MHLW) in Japan.TransMID(TM) is Xenova's lead product candidate currently in Phase III trials for the treatment of glioblastoma multiforme. The achievement of orphan drug designation triggers a milestone payment from Sosei to Xenova.
Trintech Group Plc
Trintech Announces ReconNET 7.1 for Enterprise Funds
DUBLIN, Ireland and DALLAS, Feb. 14, 2005 (PRIMEZONE) -- Trintech (Nasdaq:TTPA (Prime Standard:TTP), a leading provider of transaction reconciliation and payment infrastructure solutions, today announced the release of ReconNET 7.1, the latest version of its flagship reconciliation and account balancing application. ReconNET 7.1 features increased levels of intelligence built into the system, reducing the expertise required at the user level, and interface improvements in navigation and display to improve productivity. Additionally, ReconNET 7.1 includes expanded support for Sarbanes-Oxley financial disclosure requirements, including enhanced audit trail capabilities.
Qualcomm And Bitfone Provide 3G Wireless Software Update Technology For Mobile Devices
CANNES, France, Feb. 14, 2005 (PRIMEZONE) -- Bitfone Corporation (www.bitfone.com), the company that pioneered firmware over-the-air (FOTA) update technology for mobile phones, and QUALCOMM Incorporated (Nasdaq:QCOM), pioneer and world leader of Code Division Multiple Access (CDMA) digital wireless technology, today announced that QUALCOMM and Bitfone will provide software update capabilities initially for QUALCOMM's Mobile Station Modem(tm) (MSM(tm)) MSM6250(tm) chipset using Bitfone's mProve(tm) technology.